The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs

Chinese Journal of Lung Cancer

Volumn 13, Issue 4, 2010, Pages 375-379

  Wang, Yuli ^a   Liu, Hongyu ^a   Chen, Jun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

EGFR TKIs; Erlotinib; FISH; Gefitinib; IHC; PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN;

CANCER PAIN; CANCER THERAPY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; SHORT SURVEY; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77951579964     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2010.04.20     Document Type: Short Survey

References (43)

1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101(36): 13306-13311.
2. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol, 2005, 23(4): 857-865.
3. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005, 97(5): 339-346. (Pubitemid 40425952)
4. Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2009. [Epub ahead of print]
5. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol, 2006, 24(14): 2158-2163.
6. Yoshida K, Yatabe Y, Park J, et al. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol, 2010, 136(4): 527-535.
7. Tiseo M, Rossi G, Capelletti M, et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers. Lung Cancer, 2010, 67(3): 355-360.
8. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol, 2008, 26(9): 1472-1478.
9. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with ge!tinib. Ann Oncol, 2007, 18(4): 752-760. (Pubitemid 46523281)
10. Sone T, Kasahara K, Kimura H, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with non-small cell lung cancer. Cancer, 2007, 109(9): 1836-1844.
11. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer, 2007, 120(6): 1239-1247.
12. Sasaki H, Endo K, Okuda K, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol, 2008, 134(5): 569-577.
13. Pugh TJ, Bebb G, Barclay L, et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to ge!tinib response in a retrospective analysis of lung cancer patients. BMC Cancer, 2007, 7: 128.
14. Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridizationpositive/ phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol, 2007, 25(16): 2248-2255.
15. Gupta R, Dastane AM, McKenna R Jr, et al. The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcino ma: review of current "best evidence" with meta-analysis. Hum Pathol, 2009, 40(3): 356-365.
16. Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 2009, 6(6): 352-366.
17. Tony Mok et al. IPASS: Gefitinib (IRESSA)(TM) shows superior efficacy compared to doublet chemotherapy in phase III Asian 1st line advanced non-small cell lung cancer (NSCLC) study. Poster presented at 2008 ESMO meeting in Stockholm.
18. TRUST: Tarceva lung cancer survival treatment. Poster presented at 2008 ESMO meeting in Stockholm.
19. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res, 2009, 15(16): 5267-5273.
20. Varella-Garcia M, Mitsudomi T, Yatabe Y, et al. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol, 2009, 4(3): 318-325.
21. Sasaki H, Shimizu S, Okuda K, et al. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer, 2009, 64(3): 295-300.
22. Schneider CP, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol, 2008, 3(12): 1446-1453
23. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and ge!tinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 2005, 97(9): 643-655. (Pubitemid 40812628)
24. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol, 2005, 23(28): 6838-6845.
25. Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res, 2008, 14(19): 6317-6323.
26. Varella-Garcia M, Mitsudomi T, Yatabe Y, et al. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol, 2009, 4(3): 318-325.
27. Cherneva RV, Georgiev OB, Petrov DB, et al. Epidermal growth factor receptor gene copy number changes in lung cancer. Folia Med (Plovdiv), 2009, 51(2): 12-18.
28. Dziadziuszko R, Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res, 2006, 12(10): 3078-3084. (Pubitemid 43837354)
29. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep, 2000, 7(3): 603-607.
30. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med, 2005, 353(2): 133-144.
31. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res, 1997, 3(4): 515-522.
32. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer, 2004, 91(2): 208-212.
33. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer; the Tarceva Lung Cancer investigation Trial. J Clin Oncol, 2007, 25(12): 1545-1552.
34. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23(25): 5892-5899.
35. Morinaga R, Okamoto I, Fujita Y, et al. Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. Cancer Sci, 2008, 99(12): 2455-2460.
36. Lee HJ, Xu X, Choe G, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer, 2009 [Epub ahead of print].
37. Gupta R, Dastane AM, Forozan F, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol, 2009, 22(1): 128-133.
38. El-Zammar OA, Zhang S, Katzenstein AL, et al. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. Diagn Mol Pathol, 2009, 18(3): 133-137.
39. Raponi M, Winkler H, Dracopoli NC, et al. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol, 2008, 8(4): 413-418.
40. Riely GJ, Marks J, Pao W, et al. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc, 2009, 6(2): 201-205.
41. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol, 2008, 9(10): 962-972.
42. Ding L, Getz G, Wheeler DA, et al. somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455(7216): 1069-1075.
43. Mascaux C, Iannino N, Martin B, et al. The role of ;S oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer, 2005, 92(1): 131-139.